香雪製藥(300147.SZ):非公開發行股票決議有效期到期
格隆匯 5 月 10日丨香雪製藥(300147.SZ)公佈,公司於2020年4月8日召開2020年第一次臨時股東大會,審議通過了《關於公司2020年非公開發行股票方案的議案》等相關議案,決議有效期為股東大會通過本次發行方案之日起12 個月。在通過公司內部決策程序後,公司積極推進材料申報等有關事宜,受資本市場環境、融資時機、募投項目、行業情況等綜合因素影響,公司本次非公開發行股票事項尚未取得實質進展。截止公吿日,本次非公開發行股票方案的決策程序有效期已到期自動失效。
根據證監會、深交所關於上市公司再融資相關規定,如公司擬繼續或重新啟動非公開發行股票事宜,需按照規定重新履行董事會、監事會和股東大會的決策程序及信息披露義務。公司本次非公開發行股票方案的失效,不會對公司生產經營造成重大影響,未來公司將根據項目的推進進度及資金需求狀況,統籌安排公司融資計劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.